Skip to main content
Basmanav

News categories: Publication

Inflammatory diseases influence the course of hair loss

Asthma, atopic dermatitis or Hashimoto's thyroiditis as concomitant diseases are risk factors for clinical features associated with a poor prognosis in circular hair loss, also known as alopecia areata (AA). In patients with three atopic diseases, namely atopic dermatitis, asthma and rhinitis, the average age of onset of AA is about ten years earlier than in patients without chronic inflammatory comorbidities. This has now been established by researchers from the University Hospital Bonn (UKB) and the University of Bonn in a large cohort study of affected patients. Their results have now been published in the journal "Allergy".

Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is unpredictable and varies greatly from individual to individual. Numerous studies have shown that AA is often associated with comorbid, i.e. co-existing, chronic inflammatory diseases, which can have an impact on prognosis and clinical management. However, there is limited research on the impact of concomitant chronic inflammatory diseases on the clinical features of AA in an appropriately sized cohort. Through a cooperative network of dermatologists and AA support groups, human geneticists in Bonn have recruited a large group of approximately 3,000 affected individuals with genetic data and extensive clinical self-reporting over the past 20 years. Just over half of them also stated that they suffered from an additional chronic inflammatory disease. "This is one of the largest cohorts of AA worldwide and a unique data source for research into genetic and clinical aspects of AA," says ImmunoSensartion2 member Prof. Regina Betz from the Institute of Human Genetics at the UKB, who is also a member of the Transdisciplinary Research Area (TRA) "Life & Health" at the University of Bonn.

Last author Dr. Buket Basmanav from the Institute of Human Genetics adds: "To our knowledge, this is the most comprehensive analysis of the clinical features of AA in relation to concomitant chronic inflammatory diseases. We have simultaneously assessed multiple concomitant diseases and multiple clinical features of AA in a dataset that exceeds in size most cohort-based clinical data on AA patients previously reported in the literature." Basmanav is the leader of the Cure4HAIR project, which recently received GO-Bio start-up funding from the BMBF for the development of new therapeutics and personalized medicine for AA based on genetic research.

Connection between the clinical characteristics of AA and asthma discovered

The Bonn researchers found that comorbidity with a chronic inflammatory disease - in particular atopic dermatitis, bronchial asthma, Hashimoto's thyroiditis, rhinitis or vitiligo - was associated with the age of onset, severity and/or duration of AA. This is because AA patients with asthma, atopic dermatitis or Hashimoto's thyroiditis were significantly more likely to report early-onset, severe and long-lasting hair loss. "We found that comorbid bronchial asthma is a stronger risk factor for poor prognostic factors than comorbid atopic dermatitis or rhinitis," says first author Annika Friedrich, PhD student at the University of Bonn at UKB. "This is the first report of a significant association between comorbid asthma and the clinical features of AA in the literature."

The risk of early onset, severe and long-lasting AA gradually increased as the number of concomitant atopic diseases in AA patients increased. The mean age of onset of AA was about a decade earlier in patients suffering simultaneously from three atopic diseases, i.e. bronchial asthma, atopic dermatitis and rhinitis, than in patients without chronic inflammatory comorbidities. "We consider this to be indirect support for the hypothesis that atopic diseases can trigger the onset of alopecia areata in a subgroup of patients," says Dr. Basmanav. Prof. Regina C. Betz adds: "Based on our results, we assume that AA patients with comorbid chronic inflammatory diseases, in particular atopic dermatitis, bronchial asthma or Hashimoto's thyroiditis, could benefit from more frequent clinical monitoring and earlier therapeutic intervention."

Funding

This work was funded by the German Research Foundation (DFG, German 124 Research Foundation) as part of the German Excellence Strategy - EXC2151 -125 390873048 and supported by grants under project number 126.

Publication

Annika Friedrich et al: Comorbid bronchial asthma, atopic dermatitis, and Hashimoto's thyroiditis are risk factors for early-onset, severe, and prolonged alopecia areata; Allergy; DOI: https://doi.org/10.1111/all.16468

 

Contact

Dr. F. Buket Basmanav 
Institute of Human Genetics
Bonn University Hospital
University of Bonn 
E-Mail: Basmanav.Buket@ukbonn.de

Related news

News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview